Number of shares and votes in Medivir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the number of shares and votes in Medivir has changed as a result of redemption of share under the voluntary redemption programme resolved at the extraordinary general meeting on 20 November 2014. The new number of shares has been registered with the Swedish Companies Registration Office during March 2015.

Today, the last trading day of the month, the total number of outstanding shares in Medivir are 26,966,037, whereof 606,358 series A shares and 26,359,679 series B shares, and the total number of votes amounts to 32,423,259 votes.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.

Medivir is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 8.30 CET on 31 March 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Subscribe

Documents & Links